Conferences - Results from #60

Perioperative Chemotherapy and Targeted Therapy for Locally Advanced UTUC March 7, 2021

Genomics of Upper Tract Urothelial Carcinoma March 7, 2021

The Science of Combination Therapy in Non-Muscle-Invasive Bladder Cancer (NMIBC) March 6, 2021

The Natural History of High-Risk NMIBC: Novel Therapies Versus Cystectomy March 6, 2021

Sequential Therapy in BCG Unresponsive Disease March 6, 2021

Keynote: Racial Disparities in Bladder Cancer Clinical Trials March 6, 2021

Trial Design Considerations for Intermediate Risk Non Muscle-Invasive Bladder Cancer March 6, 2021

What Novel Therapies Can Compete (or Combine) with BCG in BCG-naïve Non-Muscle Invasive Bladder Cancer (NMIBC)? March 5, 2021

Model Systems to Facilitate Development of Therapies for Non-Muscle-Invasive Bladder Cancer March 5, 2021

Regulatory Considerations in the BCG-Naïve Non-Muscle-Invasive Bladder Cancer Setting March 5, 2021

ASCO GU 2021: The CLEAR Study of Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib and the SWOG 1500 Trial of Sunitinib, Cabozantinib, Crizotinib, and Savolitinib in Advanced Kidney Cancer: Discussion February 19, 2021

ASCO GU 2021: MK-6482 in Patients with Clear Cell Renal Cell Carcinoma: Discussion February 19, 2021

ASCO GU 2021: Back to Basics in Personalization: Returning to PTEN February 19, 2021

ASCO GU 2021: 177Lu-PSMA-617 (LuPSMA) Versus Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Progressing After Docetaxel: Updated Results Including Progression-Free Survival and Patient-Reported Outcomes (TheraP ANZUP 1603) February 19, 2021

ASCO GU 2021: Biomarker Analysis from a Randomized Phase II Study of Olaparib with or Without Cediranib in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) February 19, 2021

ASCO GU 2021: Final Results from ACIS, a Randomized, Placebo-Controlled Double-Blind Phase 3 Study of Apalutamide and Abiraterone Acetate plus Prednisone (AAP) Versus AAP in Patients with Chemo-Naive Metastatic Castration-Resistant Prostate Cancer February 19, 2021

ASCO GU 2021: Molecular Determinants Associated with Long-Term Response to Apalutamide in nmCRPC and Final Results from the ACIS Phase 3 Study - Discussion February 19, 2021

ASCO GU 2021: Australia and New Zealand Outcomes of High-Dose Chemotherapy and Stem Cell Transplantation for Relapsed or Refractory Germ Cell Tumors from 1999 to 2019: Multicenter Registry-Based Study with ABMTRR February 19, 2021

ASCO GU 2021: Longer Follow-up Data of Circulating miR371a-3p Expression Across the Spectrum of Germ Cell Tumors February 19, 2021

ASCO GU 2021: Prediction Model for Brain Metastasis in Patients with Metastatic Germ-Cell Tumors Accounting for Size of Pulmonary Metastases February 19, 2021

Page 4 of 392